Dana-Farber Cancer Institute clinical trial pipeline

16 trials changed in the last 30 days: 1 stopped, 10 with notable changes, 5 with minor changes only.

1. Stopped

   Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using…Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

   Withdrawn before enrolling

   Dana-Farber Cancer Institute·Phase 2· NCT07513324· Registry history of NCT07513324 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

2. Notable

   0 Window of Opportunity Trial of Intratumoral Seasonal Influenza…0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

   Primary and study completion pushed from Aug 30, 2026 to Aug 30, 2027

   Dana-Farber Cancer Institute·Early Phase 1· NCT06664151· Registry history of NCT06664151 on ClinicalTrials.gov (opens the registry)

   Oct 19, 2026

3. Notable

   ADEPT · ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab…ADEPT · ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab · Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

   Primary completion pushed from Mar 23, 2026 to Mar 23, 2029

   Also in this update: Study completion pushed from Sep 1, 2030 to Sep 1, 2032

   Dana-Farber Cancer Institute·Phase 2· NCT04569747· Registry history of NCT04569747 on ClinicalTrials.gov (opens the registry)

   Oct 6, 2026

4. Notable

   Impact of PReOPerative Exercise and NutritionaL Optimization on…Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial

   Primary completion pushed from Sep 1, 2026 to Jul 1, 2027

   Also in this update: Study completion pushed from Aug 7, 2027 to Dec 30, 2027

   Dana-Farber Cancer Institute·Not applicable· NCT06565052· Registry history of NCT06565052 on ClinicalTrials.gov (opens the registry)

   Sep 30, 2026

5. Notable

   Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy…Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)

   Primary completion pushed from Aug 31, 2026 to Aug 31, 2028

   Also in this update: Enrollment closed, study ongoing; Study completion pushed from Oct 31, 2026 to Oct 31, 2028

   Dana-Farber Cancer Institute·Not applicable· NCT06807294· Registry history of NCT06807294 on ClinicalTrials.gov (opens the registry)

   Sep 22, 2026

6. Notable

   YCT · Yoga on Nerve Pain Caused by Chemotherapy…YCT · Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)

   Primary and study completion pushed from Sep 30, 2026 to Sep 30, 2028

   Dana-Farber Cancer Institute·Not applicable· NCT05121558· Registry history of NCT05121558 on ClinicalTrials.gov (opens the registry)

   Sep 22, 2026

7. Notable

   Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

   Primary endpoint(s) modified

   Also in this update: Results posted: Sep 24, 2026

   Dana-Farber Cancer Institute·Phase 2· NCT04584255· Registry history of NCT04584255 on ClinicalTrials.gov (opens the registry)

   Sep 24, 2026

8. Notable

   Ibrutinib + Obinutuzumab · Relapsed or Refractory Chronic…Ibrutinib + Obinutuzumab · Relapsed or Refractory Chronic Lymphocytic Leukemia

   Primary endpoint(s) modified

   Also in this update: Results posted: Sep 22, 2026

   Dana-Farber Cancer Institute·Phase 1· NCT02537613· Registry history of NCT02537613 on ClinicalTrials.gov (opens the registry)

   Sep 22, 2026

9. Notable

   D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted…D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

   Recruitment opened

   Also in this update: Start date changed from estimate of Aug 24, 2026 to Aug 31, 2026

   Dana-Farber Cancer Institute·Phase 3· NCT07624513· Registry history of NCT07624513 on ClinicalTrials.gov (opens the registry)

   Oct 9, 2026

10. Notable

    Integrated Smartphone Technology to Alleviate Malignant Pain…Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing

    Recruitment opened

    Also in this update: Primary completion pushed from Oct 30, 2026 to Dec 30, 2026; Study completion pushed from Nov 30, 2026 to Apr 30, 2027

    Dana-Farber Cancer Institute·Not applicable· NCT06117709· Registry history of NCT06117709 on ClinicalTrials.gov (opens the registry)

    Oct 13, 2026

11. Notable

    ReduceHEAT · Wearable Thermal Devices for ADT-Induced Hot Flashes

    Recruitment opened

    Dana-Farber Cancer Institute·Not applicable· NCT07729150· Registry history of NCT07729150 on ClinicalTrials.gov (opens the registry)

    Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.